| Date | Time | Source | Headline | Symbol | Company |
| 05/01/2024 | 7:15AM | Business Wire | Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | NYSE:MRK | Merck and Co Inc |
| 04/29/2024 | 9:00AM | Business Wire | Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults | NYSE:MRK | Merck and Co Inc |
| 04/25/2024 | 4:40PM | IH Market News | U.S. Stocks Climb Well Off Worst Levels But Close Mostly Lower | NYSE:MRK | Merck and Co Inc |
| 04/25/2024 | 9:09AM | IH Market News | Futures Pointing To Sharply Lower Open On Wall Street | NYSE:MRK | Merck and Co Inc |
| 04/25/2024 | 7:52AM | IH Market News | Southwest Shares Tumble 9.6% Post $231 Million 1Q Loss, AstraZeneca Surges on 19% Annual Increase, and More on Earnings | NYSE:MRK | Merck and Co Inc |
| 04/25/2024 | 6:30AM | Business Wire | Merck Announces First-Quarter 2024 Financial Results | NYSE:MRK | Merck and Co Inc |
| 04/19/2024 | 7:04AM | PR Newswire (Canada) | Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H | NYSE:MRK | Merck and Co Inc |
| 04/19/2024 | 7:04AM | PR Newswire (Canada) | Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta | NYSE:MRK | Merck and Co Inc |
| 04/10/2024 | 7:13AM | IH Market News | Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News | NYSE:MRK | Merck and Co Inc |
| 04/04/2024 | 6:45AM | Business Wire | Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer | NYSE:MRK | Merck and Co Inc |
| 04/03/2024 | 8:00AM | Business Wire | REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer | NYSE:MRK | Merck and Co Inc |
| 04/01/2024 | 6:45AM | Business Wire | Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 | NYSE:MRK | Merck and Co Inc |
| 03/28/2024 | 6:45AM | Business Wire | European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults | NYSE:MRK | Merck and Co Inc |
| 03/27/2024 | 6:54AM | IH Market News | GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News | NYSE:MRK | Merck and Co Inc |
| 03/26/2024 | 6:21PM | Business Wire | FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) | NYSE:MRK | Merck and Co Inc |
| 03/21/2024 | 6:45AM | Business Wire | Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer | NYSE:MRK | Merck and Co Inc |
| 03/19/2024 | 9:00AM | Business Wire | Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults | NYSE:MRK | Merck and Co Inc |
| 03/15/2024 | 4:23PM | PR Newswire (US) | FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform | NYSE:MRK | Merck and Co Inc |
| 03/15/2024 | 6:45AM | Business Wire | Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer | NYSE:MRK | Merck and Co Inc |
| 03/13/2024 | 3:00AM | Business Wire | Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9 | NYSE:MRK | Merck and Co Inc |
| 03/11/2024 | 8:15AM | Business Wire | Merck Completes Acquisition of Harpoon Therapeutics, Inc. | NYSE:MRK | Merck and Co Inc |
| 03/06/2024 | 10:25AM | Business Wire | Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 | NYSE:MRK | Merck and Co Inc |
| 03/05/2024 | 9:03AM | IH Market News | Futures Pointing To Continued Weakness On Wall Street | NYSE:MRK | Merck and Co Inc |
| 03/05/2024 | 6:45AM | Business Wire | Merck to Participate in the Barclays 26th Annual Global Healthcare Conference | NYSE:MRK | Merck and Co Inc |
| 03/04/2024 | 6:45AM | Business Wire | Merck to Participate in the Leerink Partners Global Biopharma Conference 2024 | NYSE:MRK | Merck and Co Inc |
| 02/27/2024 | 6:45AM | Business Wire | Merck to Participate in the TD Cowen 44th Annual Health Care Conference | NYSE:MRK | Merck and Co Inc |
| 02/23/2024 | 6:20AM | Business Wire | Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence | NYSE:MRK | Merck and Co Inc |
| 02/20/2024 | 4:14PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:MRK | Merck and Co Inc |
| 02/20/2024 | 6:45AM | Business Wire | FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma | NYSE:MRK | Merck and Co Inc |
| 02/15/2024 | 4:03PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:MRK | Merck and Co Inc |